Triazolopyridyl compounds as aldosterone synthase inhibitors

US9567333B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• D. Jonathan Bennett · Boston, US
• Jaiqiang Cai · Glasgow, GB
• Emma Carswell · Eaglesham, GB
• Andrew Cooke · Doylestown, US
• Scott B. Hoyt · Hoboken, US
• Clare London · Chatham, US
• John MacLean · Brookline, US
• Paul Ratcliffe · Lanark, GB
• Jerry Andrew Taylor · Trenton, US
• Yusheng Xiong · Newtown, US
• Swapan Kumar Samanta · Kanchinakote, IN
• Bheemashankar A. Kulkarni · Noida, IN

Key dates

• Filing date: Oct 19, 2015
• Grant date: Feb 14, 2017
• Expiry date: Oct 19, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to triazolopyridyl compounds of the structural formula:or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.